200 related articles for article (PubMed ID: 17548045)
1. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening.
Moss ML; Rasmussen FH
Anal Biochem; 2007 Jul; 366(2):144-8. PubMed ID: 17548045
[TBL] [Abstract][Full Text] [Related]
2. Fluorescent substrates useful as high-throughput screening tools for ADAM9.
Moss ML; Rasmussen FH; Nudelman R; Dempsey PJ; Williams J
Comb Chem High Throughput Screen; 2010 May; 13(4):358-65. PubMed ID: 20015014
[TBL] [Abstract][Full Text] [Related]
3. Fluorescent substrates for ADAM15 useful for assaying and high throughput screening.
Moss ML; Miller MA; Vujanovic N; Yoneyama T; Rasmussen FH
Anal Biochem; 2016 Dec; 514():42-47. PubMed ID: 27637923
[TBL] [Abstract][Full Text] [Related]
4. An improved fluorescent substrate for assaying soluble and membrane-associated ADAM family member activities.
Moss ML; Minond D; Yoneyama T; Hansen HP; Vujanovic N; Rasmussen FH
Anal Biochem; 2016 Aug; 507():13-7. PubMed ID: 27177841
[TBL] [Abstract][Full Text] [Related]
5. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.
Rapti M; Atkinson SJ; Lee MH; Trim A; Moss M; Murphy G
Biochem J; 2008 Apr; 411(2):433-9. PubMed ID: 18215140
[TBL] [Abstract][Full Text] [Related]
6. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
Pruessmeyer J; Ludwig A
Semin Cell Dev Biol; 2009 Apr; 20(2):164-74. PubMed ID: 18951988
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates.
Minond D; Cudic M; Bionda N; Giulianotti M; Maida L; Houghten RA; Fields GB
J Biol Chem; 2012 Oct; 287(43):36473-87. PubMed ID: 22927435
[TBL] [Abstract][Full Text] [Related]
8. Improved synthesis of ADAM10 inhibitor GI254023X.
Hoettecke N; Ludwig A; Foro S; Schmidt B
Neurodegener Dis; 2010; 7(4):232-8. PubMed ID: 20197648
[TBL] [Abstract][Full Text] [Related]
9. ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha.
Le Gall SM; Bobé P; Reiss K; Horiuchi K; Niu XD; Lundell D; Gibb DR; Conrad D; Saftig P; Blobel CP
Mol Biol Cell; 2009 Mar; 20(6):1785-94. PubMed ID: 19158376
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and in vitro Evaluation of ADAM10 and ADAM17 Highly Selective Bioimaging Probes.
Camodeca C; Nuti E; Tosetti F; Poggi A; D'Arrigo C; Zocchi MR; Rossello A
ChemMedChem; 2018 Oct; 13(19):2119-2131. PubMed ID: 30102846
[TBL] [Abstract][Full Text] [Related]
11. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules.
Ludwig A; Hundhausen C; Lambert MH; Broadway N; Andrews RC; Bickett DM; Leesnitzer MA; Becherer JD
Comb Chem High Throughput Screen; 2005 Mar; 8(2):161-71. PubMed ID: 15777180
[TBL] [Abstract][Full Text] [Related]
12. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events.
Moss ML; Bomar M; Liu Q; Sage H; Dempsey P; Lenhart PM; Gillispie PA; Stoeck A; Wildeboer D; Bartsch JW; Palmisano R; Zhou P
J Biol Chem; 2007 Dec; 282(49):35712-21. PubMed ID: 17895248
[TBL] [Abstract][Full Text] [Related]
13. Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts.
Mezyk-Kopeć R; Bzowska M; Stalińska K; Chełmicki T; Podkalicki M; Jucha J; Kowalczyk K; Mak P; Bereta J
Cytokine; 2009 Jun; 46(3):309-15. PubMed ID: 19346138
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy.
Fedak PW; Moravec CS; McCarthy PM; Altamentova SM; Wong AP; Skrtic M; Verma S; Weisel RD; Li RK
Circulation; 2006 Jan; 113(2):238-45. PubMed ID: 16401770
[TBL] [Abstract][Full Text] [Related]
15. Activation of the P2X7 receptor induces the rapid shedding of CD23 from human and murine B cells.
Pupovac A; Geraghty NJ; Watson D; Sluyter R
Immunol Cell Biol; 2015 Jan; 93(1):77-85. PubMed ID: 25155463
[TBL] [Abstract][Full Text] [Related]
16. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
17. The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?
Saftig P; Reiss K
Eur J Cell Biol; 2011; 90(6-7):527-35. PubMed ID: 21194787
[TBL] [Abstract][Full Text] [Related]
18. ADAM9 inhibition increases membrane activity of ADAM10 and controls α-secretase processing of amyloid precursor protein.
Moss ML; Powell G; Miller MA; Edwards L; Qi B; Sang QX; De Strooper B; Tesseur I; Lichtenthaler SF; Taverna M; Zhong JL; Dingwall C; Ferdous T; Schlomann U; Zhou P; Griffith LG; Lauffenburger DA; Petrovich R; Bartsch JW
J Biol Chem; 2011 Nov; 286(47):40443-51. PubMed ID: 21956108
[TBL] [Abstract][Full Text] [Related]
19. Metalloprotease inhibitor profiles of human ADAM8 in vitro and in cell-based assays.
Schlomann U; Dorzweiler K; Nuti E; Tuccinardi T; Rossello A; Bartsch JW
Biol Chem; 2019 May; 400(6):801-810. PubMed ID: 30738011
[TBL] [Abstract][Full Text] [Related]
20. LC-MS based cleavage site profiling of the proteases ADAM10 and ADAM17 using proteome-derived peptide libraries.
Tucher J; Linke D; Koudelka T; Cassidy L; Tredup C; Wichert R; Pietrzik C; Becker-Pauly C; Tholey A
J Proteome Res; 2014 Apr; 13(4):2205-14. PubMed ID: 24635658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
